Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lee Schwartzberg

Showing results (31-40 of 112) with videos related to

Pageof 12
Sort By:
Journal of Personalized Medicine|December 2, 2020
Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community SettingAri VanderWalde, Axel Grothey, Daniel Vaena, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 29, 2010
Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancerRobert Klein, Ron Wielage, Catherine Muehlenbein, et al.
Clinical Breast Cancer|December 31, 2005
Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weeklyFrank M Senecal, Lorrin Yee, Nashat Gabrail, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 29, 2005
Impact of chemotherapy-induced neutropenia on quality of life: a prospective pilot investigationBarry V Fortner, Lee Schwartzberg, Kurt Tauer, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 22, 2013
Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV)Lee Schwartzberg, Sally Y Barbour, Gary R Morrow, et al.
The Journal of Community and Supportive Oncology|April 2, 2015
Palonosetron versus older 5-HT3 receptor antagonists for nausea prevention in patients receiving chemotherapy: a multistudy analysisGary R Morrow, Lee Schwartzberg, Sally Y Barbour, et al.
Clinical Breast Cancer|July 25, 2008
Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancerCraig Bunnell, Linda Vahdat, Lee Schwartzberg, et al.
Clinical Breast Cancer|July 16, 2014
Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancerSharon Wilks, Shannon Puhalla, Joyce O'Shaughnessy, et al.
BMC Cancer|October 27, 2010
Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trialLee Schwartzberg, Ronald Burkes, Barry Mirtsching, et al.
Drugs in Context|April 11, 2017
NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UKHelene Cawston, Francois Bourhis, Jennifer Eriksson, et al.
Pageof 12

Showing results (31-40 of 112) with videos related to

Sort By:
Pageof 12
Journal of Personalized Medicine|December 2, 2020
Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community SettingAri VanderWalde, Axel Grothey, Daniel Vaena, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 29, 2010
Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancerRobert Klein, Ron Wielage, Catherine Muehlenbein, et al.
Clinical Breast Cancer|December 31, 2005
Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weeklyFrank M Senecal, Lorrin Yee, Nashat Gabrail, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 29, 2005
Impact of chemotherapy-induced neutropenia on quality of life: a prospective pilot investigationBarry V Fortner, Lee Schwartzberg, Kurt Tauer, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 22, 2013
Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV)Lee Schwartzberg, Sally Y Barbour, Gary R Morrow, et al.
The Journal of Community and Supportive Oncology|April 2, 2015
Palonosetron versus older 5-HT3 receptor antagonists for nausea prevention in patients receiving chemotherapy: a multistudy analysisGary R Morrow, Lee Schwartzberg, Sally Y Barbour, et al.
Clinical Breast Cancer|July 25, 2008
Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancerCraig Bunnell, Linda Vahdat, Lee Schwartzberg, et al.
Clinical Breast Cancer|July 16, 2014
Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancerSharon Wilks, Shannon Puhalla, Joyce O'Shaughnessy, et al.
BMC Cancer|October 27, 2010
Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trialLee Schwartzberg, Ronald Burkes, Barry Mirtsching, et al.
Drugs in Context|April 11, 2017
NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UKHelene Cawston, Francois Bourhis, Jennifer Eriksson, et al.
Pageof 12